The comparable efficacy of denosumab on bone mineral density in rheumatoid arthritis patients with postmenopausal osteoporosis: A retrospective case-control study

被引:0
|
作者
Kim, Seong-Kyu [1 ,2 ]
Kim, Ji-Won [1 ]
Lee, Hwajeong [1 ]
Park, Sung-Hoon [1 ]
Choe, Jung-Yoon [1 ]
Kim, Boyoung [1 ]
机构
[1] Catholic Univ Daegu, Dept Internal Med, Div Rheumatol, Sch Med, Daegu, South Korea
[2] Catholic Univ Daegu, Dept Internal Med, Div Rheumatol, Sch Med, 33 Duryugongwon Ro 17 Gil, Daegu 42472, South Korea
关键词
bisphosphonate; BMD; denosumab; osteoporosis; SERMs; OSTEOCLAST DIFFERENTIATION; TURNOVER MARKERS; DOUBLE-BLIND; DIAGNOSIS; METHOTREXATE; MULTICENTER; RECEPTOR; COLLEGE; EROSION; LIGAND;
D O I
10.1097/MD.0000000000034219
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Little is known about differences in the therapeutic efficacy of denosumab in subjects with and without rheumatoid arthritis (RA). This study compares the changes in bone mineral density (BMD) between RA patients and controls without RA who had been treated with denosumab for 2 years for postmenopausal osteoporosis. A total of 82 RA patients and 64 controls were enrolled, who were refractory to selective estrogen receptor modulators (SERMs) or bisphosphonates and completed the treatment of denosumab 60 mg for 2 years. The efficacy of denosumab in RA patients and controls was assessed using areal BMD (aBMD) and T-score of the lumbar spine, femur neck, and total hip. A general linear model with repeated measures analysis of variance was used to determine differences in aBMD and T-score between 2 study groups. No significant differences in percent changes in aBMD and T-scores by denosumab treatment for 2 years at the lumbar spine, femur neck, and total hip were evident between RA patients and controls (P > .05 of all), except T-score of the total hip (P = .034). Denosumab treatment equally increased aBMD at the lumbar spine and T-scores at the lumbar spine and total hip between RA patients and controls without statistical differences, but RA patients showed less improvement in aBMD at the femur neck (p(time*group) = 0.032) and T-scores at the femur neck and total hip than controls (p(time*group) = 0.004 of both). Changes in aBMD and T-scores after denosumab treatment in RA patients were not affected by previous use of bisphosphonates or SERMs. Differences of T-score at the femur neck among previous bisphosphonate users and aBMD and T-score at the femur neck and T-scores at the total hip were evident. This study revealed that 2 years of denosumab treatment in female RA patients achieved comparable efficacy on BMD to controls at the lumbar spine, but showed somewhat insufficient improvement at the femur neck and total hip.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] EFFICACY OF DENOSUMAB ON BONE MINERAL DENSITY IN PATIENTS WITH POSTMENOPAUSAL OSTEOPOROSIS
    Tsagareli, M.
    Giorgadze, E.
    Dolidze, N.
    Sulikashvili, T.
    Jeiranashvili, N.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2016, 27 : S252 - S252
  • [2] THE INFLUENCE OF DENOSUMAB ON BONE MINERAL DENSITY, STRUCTURAL DAMAGE IN PATIENTS WITH OSTEOPOROSIS AND RHEUMATOID ARTHRITIS
    Dydykina, P.
    Petrova, E.
    Dydykina, I.
    Smirnov, A.
    Glukhova, S.
    Alexeeva, L.
    Nasonov, E.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 1021 - 1021
  • [3] Denosumab significantly improves bone mineral density with or without bisphosphonate pre-treatment in osteoporosis with rheumatoid arthritis Denosumab improves bone mineral density in osteoporosis with rheumatoid arthritis
    Nakamura, Yukio
    Suzuki, Takako
    Kato, Hiroyuki
    [J]. ARCHIVES OF OSTEOPOROSIS, 2017, 12 (01)
  • [4] Efficacy and Safety of Denosumab in Osteoporosis or Low Bone Mineral Density Postmenopausal Women
    Chen, Yi
    Zhu, Jun
    Zhou, Yiqin
    Peng, Jinhui
    Wang, Bo
    [J]. FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [5] THE EFFECTS OF DENOSUMAB TREATMENT ON BONE MINERAL DENSITY, STRUCTURAL DAMAGE IN PATIENTS WITH OSTEOPOROSIS AND RHEUMATOID ARTHRITIS
    Dydykina, P.
    Dydykina, I.
    Petrova, E.
    Smirnov, A.
    Glukhova, S.
    Alekseeva, L.
    Nasonov, E.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2015, 26 : S315 - S315
  • [6] Denosumab increases bone mineral density in patients with rheumatoid arthritis.
    Dore, R.
    Hurd, E.
    Palmer, W.
    Shergy, W.
    Zhou, L.
    Newmark, R.
    Tsuji, W.
    Dore, Robin K.
    [J]. ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S240 - S240
  • [7] EFFICACY OF DENOSUMAB FOR CONTROL OF BONE MINERAL DENSITY AND MICROARCHITECTURE IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS: A ONE-YEAR EXPERIENCE
    Petranova, Tsvetanka
    Sheytanov, Ivan
    Monov, Simeon
    Rashkov, Rasho
    Kinov, Plamen
    [J]. BIOTECHNOLOGY & BIOTECHNOLOGICAL EQUIPMENT, 2013, 27 (04) : 3977 - 3981
  • [8] EFFICACY OF DENOSUMAB ON BONE MINERAL DENSITY AND MICROARCHITECTURE IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS WITH AND WITHOUT GLUCOCORTICOID TREATMENT
    Petranova, T.
    Sheytanov, I.
    Monov, S.
    Peytcheva, V.
    Rashkov, R.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2014, 25 : S64 - S65
  • [9] Denosumab significantly improves bone mineral density with or without bisphosphonate pre-treatment in osteoporosis with rheumatoid arthritisDenosumab improves bone mineral density in osteoporosis with rheumatoid arthritis
    Yukio Nakamura
    Takako Suzuki
    Hiroyuki Kato
    [J]. Archives of Osteoporosis, 2017, 12
  • [10] Determination of serum bone-related minerals during denosumab treatment in osteoporosis patients with rheumatoid arthritis Mineral change by denosumab in osteoporosis with rheumatoid arthritis
    Suzuki, Takako
    Nakamura, Yukio
    Kato, Hiroyuki
    [J]. CLINICAL NUTRITION ESPEN, 2018, 26 : 53 - 56